Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with advanced melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer. Recombinant interleukin-15 may kill tumor cells by stopping blood flow to the tumor and by stimulating white blood cells to kill melanoma, kidney, non-small cell lung, and squamous cell head and neck cancer cells.

Stanford Investigator(s)

CONTACT INFORMATION

Primary Contact:
Brenda Hann
(650) 723-0966